ReflectivAI

Request Demo

← All insights

· 5 min read · Tony Abdelmalak

From Experimentation to Operationalization: The 2026 Shift in Commercial AI Scaling

MIT's widely-cited 2025 report found that 95% of enterprise generative AI pilots fail to deliver measurable financial return, and only about 5% reach scaled production.

Everyone is talking about AI adoption. Very few people are talking about AI operation.

That gap is the story of the last two years, and it's about to become the defining story of 2026.

Pharma and life sciences companies have spent enormous energy proving AI can work in a demo, a pilot, a proof of concept. Far less energy has gone into proving it can work on a Tuesday afternoon, in a real territory, with a real rep, in front of a real physician.

The Pilot Graveyard Is Bigger Than Anyone Wants to Admit

The numbers are not subtle.

According to MIT's 2025 report, based on 150 interviews with leaders, a survey of 350 employees, and an analysis of 300 public AI deployments, found that 95% of enterprise generative AI pilots fail to deliver measurable financial return. Only about 5% reach scaled production. As the report put it, "The 95% failure rate for enterprise AI solutions represents the clearest manifestation of the GenAI Divide."

That's not a rounding error. That's an entire industry mistaking activity for progress.

Pharma isn't an exception to this pattern. It's arguably a sharper example of it. Industry data presented at Axtria Ignite 2026 found that 89% of AI pilots never reach production One pharma leader at that same conference summed it up: "We have a Ferrari, we just don't know how to drive it."

That line should sit uncomfortably with every commercial leader reading this.

Why Generic Tools Break Down in the Field

The failure isn't really about the models. It's about generic tools pretending they work like purpose-built ones once they hit a real workflow.

Aditya Challapally, the MIT report's lead author, explained it plainly: "Generic tools like ChatGPT excel for individuals because of their flexibility, but they stall in enterprise use since they don't learn from or adapt to workflows."

Field commercial work is workflow. Almost entirely.

Call planning. Objection handling. Message sequencing. Territory judgment built up over years of pattern recognition.

A tool that doesn't adapt to that context isn't failing because it's weak. It's failing because it was never designed to notice what matters in that specific room, with that specific customer, on that specific day.

That's a design problem, not a capability problem. And it's exactly why most life sciences organizations are still stuck at the pilot stage.

McKinsey Sees the Same Pattern, and a Bigger Number Behind It

McKinsey's life sciences research points to the same structural issue. Years after gen AI tools became widely available, the firm put it this way: This instinct to capture short-term value through experimentation, coupled with the federated/function-led structure of many life science organizations, explains many of the challenges organizations encounter when it comes to scaling.

In other words, lots of teams running lots of small experiments. Few of them ever connecting into something an organization can actually rely on.

That's a real cost, because the upside isn't small. McKinsey Global Institute estimates that gen AI could generate $60 billion to

10 billion annually in economic value for pharmaceutical and medtech companies, with
8 billion to $30 billion of that value attributed to commercial functions alone.

Eighteen to thirty billion dollars sitting specifically in commercial. Not R&D. Not manufacturing. The conversations happening between reps, medical liaisons, and providers every single day.

That's the opportunity everyone claims to want. It's also the one most organizations are least structured to capture.

Automation Isn't the Answer. Judgment Is.

Here's where I think the industry keeps getting the next move wrong.

The instinct, once a pilot fails, is to reach for more automation. Bigger agents. Fewer humans in the loop. Faster deployment.

I don't think that's the fix. The data backs that up. An industry survey specific to pharma found that independent benchmarks show agents completing only 24–58% of realistic enterprise tasks unassisted. That's not a small variance. That's a coin flip on a good day.

Unsupervised automation in a high-stakes, regulated conversation isn't a shortcut. It's a liability with better UX.

What actually scales is something narrower and less flashy: making the judgment already happening inside a conversation visible so it can be coached, governed, and improved. Noticing a signal. Interpreting it correctly. Responding in a way that respects the moment and the compliance boundaries around it.

That's not a model problem. That's a measurement problem, and it's a human-led one.

Operationalization Looks Different Than Experimentation

Experimentation asks: can this tool do something impressive?

Operationalization asks something harder: can this behavior be seen, verified, and trusted at scale, across every rep, every territory, every week, without depending on the tool to make the call?

Those are not the same question. And 2026 is the year the difference stops being theoretical.

The organizations that move past the 5% mark won't be the ones with the flashiest agent. They'll be the ones that decided early that judgment inside the conversation is the thing worth making visible and governable, not the thing worth automating away.

The Ferrari isn't the problem. Knowing how to drive it, consistently, safely, and in a way you can actually measure, that's the whole game now.

What would it take for your organization to trust what's actually happening in the field conversation, not just the dashboard summarizing it afterward?

Sources